Clay Siegall, Seattle Genetics’ president and chief executive officer, said the company’s three leading drug candidates are moving well through clinical trials.
www.heraldnet.com/article/20080425/BIZ/779506074/1005
Talk to us
> Give us your news tips.
> Send us a letter to the editor.
> More Herald contact information.
